Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience.
Altamura C, Brunelli N, Marcosano M, Aurilia C, Egeo G, Lovati C, Favoni V, Perrotta A, Maestrini I, Schiano Di Cola F, d'Onofrio F, Finocchi C, Bertuzzo D, Bono F, Ranieri A, Albanese M, Messina R, Doretti A, Di Piero V, Cevoli S, Barbanti P, Vernieri F; GARLIT Study Group. Altamura C, et al. Among authors: doretti a. J Neurol. 2022 Nov;269(11):5848-5857. doi: 10.1007/s00415-022-11226-4. Epub 2022 Jun 28. J Neurol. 2022. PMID: 35763113 Free PMC article.
Ecological Validity of the Montreal Cognitive Assessment in Non-Demented Parkinson's Disease Patients.
Aiello EN, D'Iorio A, Solca F, Torre S, Colombo E, Maranzano A, De Lorenzo A, Patisso V, Treddenti M, Morelli C, Doretti A, Maderna L, Verde F, Ferrucci R, Barbieri S, Ruggiero F, Priori A, Silani V, Ticozzi N, Santangelo G, Ciammola A, Poletti B. Aiello EN, et al. Among authors: doretti a. Neurodegener Dis. 2022;22(3-4):159-163. doi: 10.1159/000532115. Epub 2023 Jul 21. Neurodegener Dis. 2022. PMID: 37482058
Pyrimethamine significantly lowers cerebrospinal fluid Cu/Zn superoxide dismutase in amyotrophic lateral sclerosis patients with SOD1 mutations.
Lange DJ, Shahbazi M, Silani V, Ludolph AC, Weishaupt JH, Ajroud-Driss S, Fields KG, Remanan R, Appel SH, Morelli C, Doretti A, Maderna L, Messina S, Weiland U, Marklund SL, Andersen PM. Lange DJ, et al. Among authors: doretti a. Ann Neurol. 2017 Jun;81(6):837-848. doi: 10.1002/ana.24950. Epub 2017 Jun 9. Ann Neurol. 2017. PMID: 28480639 Free PMC article. Clinical Trial.
Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study).
Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G, Fofi L, Favoni V, Pierangeli G, Lovati C, Aguggia M, d'Onofrio F, Doretti A, Di Fiore P, Finocchi C, Rao R, Bono F, Ranieri A, Albanese M, Cevoli S, Barbanti P; GARLIT Study Group. Vernieri F, et al. Among authors: doretti a. J Headache Pain. 2021 May 3;22(1):35. doi: 10.1186/s10194-021-01247-1. J Headache Pain. 2021. PMID: 33941080 Free PMC article.
Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance.
Sacco S, Lampl C, Maassen van den Brink A, Caponnetto V, Braschinsky M, Ducros A, Little P, Pozo-Rosich P, Reuter U, Ruiz de la Torre E, Sanchez Del Rio M, Sinclair AJ, Martelletti P, Katsarava Z; Burden and Attitude to Resistant and Refractory (BARR) Study Group. Sacco S, et al. J Headache Pain. 2021 May 18;22(1):39. doi: 10.1186/s10194-021-01252-4. J Headache Pain. 2021. PMID: 34006218 Free PMC article.
Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter, Italian real-life study.
Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G, Fofi L, Favoni V, Lovati C, Bertuzzo D, d'Onofrio F, Doretti A, Di Fiore P, Finocchi C, Schiano Di Cola F, Ranieri A, Colombo B, Bono F, Albanese M, Cevoli S, Barbanti P; GARLIT Study Group. Vernieri F, et al. Among authors: doretti a. Eur J Neurol. 2022 Apr;29(4):1198-1208. doi: 10.1111/ene.15197. Epub 2021 Dec 6. Eur J Neurol. 2022. PMID: 34826192
Maintenance of response and predictive factors of 1-year GalcanezumAb treatment in real-life migraine patients in Italy: The multicenter prospective cohort GARLIT study.
Vernieri F, Brunelli N, Marcosano M, Aurilia C, Egeo G, Lovati C, Favoni V, Perrotta A, Maestrini I, Rao R, d'Onofrio L, Finocchi C, Aguggia M, Bono F, Ranieri A, Albanese M, Di Piero V, Cevoli S, Altamura C, Barbanti P; GARLIT Study Group. Vernieri F, et al. Eur J Neurol. 2023 Jan;30(1):224-234. doi: 10.1111/ene.15563. Epub 2022 Sep 26. Eur J Neurol. 2023. PMID: 36097739 Free PMC article.
61 results